Replies to post #16718 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Results: All formats performed in a similar manner (r>0.85). The table below shows the results:

Cancer type
Nr of Cancers
Nr of Normals
Cutoff (Units)
Sensitivity
Specificity

Liver *
15
128
4,900
100%
94%

Pancreatic #
10
50
4,600
100%
95%

Stomach 1st study *
48
40
4,600
90%
98%

Stomach 2nd study *
15
128
4,550
100%
94%

Colorectal &
51
85
4,800
100%
93%


If anyone is not blown away then you don't have a clue. IMO, we will see many collaborations and licenses. You can see why Dr Moro is confident about the future of our company.

Sorry to the naysayers. What you see is what you get. No more no less. SPIN THAT!!!!!!!! You have to be on board now. Those are not small samples and you cannot fudge the data.
Also look at the type of cancers. There presently are not any markers